Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.61 |
| ▸ | PRCP | P42785 | 1/20 | 0.56 |
| ▸ | CD44 | P16070 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL20358513 | 0.98 | PNMT (0.96) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL1124149 | 0.98 | PNMT (0.96) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL11331868 | 0.89 | PNMT (0.79) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL10879871 | 0.86 | PNMT (0.75) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL2750868 | 0.84 | PNMT (0.72) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL30199571 | 0.84 | PNMT (0.72) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL14677593 | 0.84 | PNMT (0.72) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL1124563 | 0.82 | PNMT (0.70) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL31158975 | 0.81 | PNMT (0.68) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL3171440 | 0.81 | PNMT (0.68) | PNMTADRA2AADRA2BADRA2CCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115043837-B | Synthesis method and application of 4-imidazo-pyridinyl-thio-isoquinoline heterocyclic compound | 河南工业大学 | 2024-02-20 | — | — | CN | claimed |
| CN-115043837-A | Synthesis method and application of 4-imidazopyridinylthioisoquinoline heterocyclic compound | 河南工业大学 | 2022-09-13 | — | — | CN | claimed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-115043837-B | Synthesis method and application of 4-imidazo-pyridinyl-thio-isoquinoline heterocyclic compound | 河南工业大学 | 2024-02-20 | — | — | CN | disclosed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220402897-A1 | CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-12-22 | — | — | US | disclosed |
| CN-115043837-A | Synthesis method and application of 4-imidazopyridinylthioisoquinoline heterocyclic compound | 河南工业大学 | 2022-09-13 | — | — | CN | disclosed |
| EP-1448547-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040128-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| CN-1087294-C | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2002-07-10 | — | — | CN | disclosed |
| CN-1261883-A | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2000-08-02 | — | — | CN | disclosed |
| EP-0038177-B1 | ANTIALLERGIC IMIDODISULFAMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BECKMAN CORPORATION (US) | 1983-08-31 | — | — | EP | disclosed |
| US-4315935-A | INHIBITING THE SYMPTOMS OF ASTHMA | SMITHKLINE CORPORATION (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0038177-A1 | Antiallergic imidodisulfamides, pharmaceutical compositions containing them and process for their preparation | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | PNMT 3529/4885ADRA2A 4682/4885ADRA2B 4693/4885 |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HAVCR2, CYP7A1, CYP26B1 | PNMT 2821/4885ADRA2A 1477/4885ADRA2B 601/4885 |
| US-20220402897-A1 | CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HAVCR2, CYP7A1, CYP26B1 | PNMT 2821/4885ADRA2A 1477/4885ADRA2B 601/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | PNMT 559/4885ADRA2A 7/4885ADRA2B 9/4885 |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | PNMT 265/4885ADRA2A 4/4885ADRA2B 5/4885 |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | GRIN1, GRIN2C, GRIN2A | PNMT 457/4885ADRA2A 616/4885ADRA2B 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.